NervGen Pharma Commences Underwritten Public Offering of Common Shares and Warrants
NervGen Pharma Corp. announced that it has commenced an underwritten public offering of common shares and accompanying warrants to purchase common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase common shares and accompanying warrants to purchase common shares. All of the common shares, pre-funded warrants and accompanying common share warrants to be sold in the offering will be offered by NervGen. The company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to advance NVG-291 through clinical studies and for general corporate and working capital purposes. Leerink Partners and TD Cowen are acting as joint bookrunning managers for the offering.
